The FDA’s recent approval of Truvada for PrEP was based on medical evidence regarding the drug’s safety and effectiveness in protecting HIV-negative people from becoming infected with HIV if taken as indicated. Several clinical trials have provided strong evidence that Truvada works for HIV prevention use. The FDA’s decision means providers can now prescribe this drug for PrEP, use which potentially opens doors for Truvada to be covered for PrEP by private insurance companies and public insurance programs.
Data from PrEP demonstration projects and additional advocacy efforts will be important to figure out the programmatic and political issues with making PrEP available to those who need it most. Thankfully, many stakeholders are thinking about these issues. Visit the website PrEP Watch to learn more about breaking news, PrEP status updates, testimony from the FDA advisory committee hearing, and statements from advocacy organizations across the country.